Cytotoxic effects of antiproliferative agents on human retinal glial cells in vitro

International Ophthalmology

Volumn 24, Issue 4, 2001, Pages 225-231

  Cai, JiPing ^a   Wei, RuiLi ^a   Ma, Xiao Ye ^a   Zhu, Huang ^a   Li, You ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cell proliferation; Glial cell; Harringtonine; Retinal cell culture

Indexed keywords

COLCHICINE; DAUNORUBICIN; FLUOROURACIL; GLIAL FIBRILLARY ACIDIC PROTEIN; HARRINGTONINE; VIMENTIN;

ADULT; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; FIBROBLAST CULTURE; GLIA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; RETINA; STATISTICAL SIGNIFICANCE; VITREORETINOPATHY; VITREOUS BODY;

ADULT; ANTINEOPLASTIC AGENTS; CELL COUNT; CELL DIVISION; CELLS, CULTURED; COLCHICINE; DAUNORUBICIN; FLUOROURACIL; HARRINGTONINES; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, ELECTRON; NEUROGLIA; RETINA;

EID: 0242500849     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022509614815     Document Type: Article

References (51)

1. Machemer R, Laqua H. Pigment epithelial proliferation in retinal detachment: (Massive periretinal proliferation). Am J Ophthalmol 1975; 80: 1-23.
2. Machemer R. Pathogenesis and classification of massive peri-retinal proliferation. Br J Ophthalmol 1978; 62: 737-747.
3. Mandelcorn MS, Machemer R, Fineberg E. Proliferation and metaplasia of intravitreal retinal pigment epithelial cell autotransplants. Am J Ophthalmol 1975; 80: 227-237.
4. Kampid A, Kenyon KR, Michels RG, Green WR, De La Cruz Z. Epiretinal and vitreous membranes: A comparative study of 56 cases. Arch Ophthalmol 1981; 99: 1445-1454.
5. Jerdan JS, Pepose JS, Michels RG, Hayashi H, Bustros SD, Sebag M, et al. Proliferative vitreoretinopathy membrane: An immunohistochemical study. Ophthalmology 1989; 96: 801-810.
6. Sternberg P, Machemer R. Subretinal proliferation. Am J Ophthalmol 1984; 98: 456-462.
7. Bringmann A, Pannicke T, Moll V, Milenkovic I, Faude F, Enzmann V, et al. Upregulation of P2X(7) receptor currents in Muller glial cells during proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2001; 42: 860-867.
8. Nork TM, Wallow IHL, Sramek SJ, Anderson G. Muller's cell involvement in proliferative diabetic retinopathy. Arch Ophthalmol 1987; 105: 1424-1429.
9. Foos RY, Kreiger AE, Mofsinger K. Pathogenic study following vitrectomy for proliferative diabetic retinopathy. Retina 1985; 5: 101-106.
10. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Nakamura M. New insights into the pathophysiology of diabetic retinopathy: Potential cell-specific therapeutic targets. Diabetes Technol Ther 2000; 2: 601-608.
11. Noble KG, Carr RE. Idiopathic preretinal gliosis. Ophthalmology 1982; 89: 521-525.
12. Chan C-C, Palestine AJ, Kuwabara T, Nussenblatt RB. Immunopathologic study of Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1988; 105: 607-611.
13. Reale E, Groos S, Luciano L, Eckardt C, Eckardt U. Membrana limitans interna and epiretinal membrane lying on macular holes. Some morphological observations. Ital J Anat Embryol 2001; 106: 509-515.
14. DeJuan E, Gridz DC, Machemer R. Ultrastructural characteristics of proliferative tissue in retinopathy of prematurity. Am J Ophthalmol 1987; 104: 149-156.
15. Smiddy WE, Green WR, Michels RG, De La Cruz Z. Ultrastructural studies of vitreomacular traction syndrome. Am J Ophthalmol 1989; 107: 177-185.
16. Kono T, Kohno T, Inomata H. Epiretinal membrane formation: Light and electron microscopic study in an experimental rabbit model. Arch Ophthalmol 1995; 113: 359-364.
17. Michels RG. Surgery of retinal detachment with proliferative vitreoretinopathy. Retina 1984; 4: 61-83.
18. Glaser BM, Cardon A, Biscoe B. Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology 1987; 94: 327-332.
19. Blumenkranz MS, Hernandez E, Ophir A. 5-Fluorouracil: New applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 1984; 91: 122-130.
20. Rubsamen PE, Davis PA, Hernandez E, O'Grady GE, Cousins SW. Prevention of experimental proliferative vitreoretinapathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch Ophthalmol 1994; 112: 407-413.
21. Lemor M, Yei JH, Glaser BM. Oral colchicine for the treatment of experimental traction retinal detachment. Arch Ophthalmol 1986; 104: 1226-1229.
22. Wiedemann P, Lemmen K, Schmiedl R, Heimann K. Intraocular daunomycin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am J Ophthalmol 1987; 104: 10-14.
23. Steinhorst UH, Chen EP, Hatchell DL, Samsa GP, Salloupis PT, Westendorf J, et al. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1993; 34: 1753-1760.
24. Lemor M, Bustros S, Glaser BM. Low-dose colchicine inhibits astrocyte, fibroblast, and retinal pigment epithelial cell migration and proliferation. Arch Ophthalmol 1986; 104: 1223-1225.
25. Koutsandrea CN, Miceli MV, Peyman GA, Farahat HG, Niesman MR. Ciprofloxacin and dexamethasone inhibit the proliferation of human retinal pigment epithelial cells in culture. Curr Eye Res 1991; 10: 249-258.
26. Mojon D, Boscoboinik D, Haas A, Bohnke M, Azzi A. Vitamin E inhibits retinal pigment epithelium cell proliferation in vitro. Ophthalmic Res 1994; 26: 304-309.
27. Puro DG, Mano T, Chan C-C, Fukuda M, Shimada H. Thrombin stimulates the proliferation of human retinal glial cells. Graefe's Arch Clin Exp Ophthalmol 1990; 228: 169-173.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
29. Eng LF, De Armond SJ. Immunochemistry of the glial fibrillary acidic protein. Prog Neuropathol 1983; 5: 19-39.
30. Guerin CJ, Wolfshagen RW, Eifring DE. Immunocytochemical identification of retinal glia as a component of human epiretinal membranes. Invest Ophthalmol Vis Sci 1990; 31: 1483-1487.
31. Lewis GP, Matsumoto B, Fisher SK. Changes in the organization and expression of cytoskeletal proteins during retinal degeneration induced by retinal detachment. Invest Ophthalmol Vis Sci 1995; 36: 2404-2416.
32. Cook B, Lewis GP, Fisher SK, Adler R. Apoptotic photoreceptor degeneration in experimental retinal detachment. Invest Ophthalmol Vis Sci 1995; 36: 990-996.
33. Verdoorn C, Lavakette RD, Dalma-Weizhausz J, Orn GM, Sorgente N, Ryan SJ. Cellular migration, proliferation, and contraction. An in vitro approach to a clinical problem-proliferative vitreoretinopathy. Arch Ophthalmol 1986; 104: 1216-1219.
34. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteriods. Am J Ophthalmol 1980; 89: 131-136.
35. Feldman EJ, Arlin Z, Ahmed T. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia 1992; 6: 1189-1191.
36. Feldman EJ, Seiter KP, Ahmed T. Homoharringtonine in patients with melodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 1996; 10: 40-42.
37. Kantarjian HM, Talpaz M, Smith TL. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol 2000; 18: 3513-3521.
38. O'Dwyer PJ, King SA, Hoth DF, Suffness M, Leyand-Jones B. Homoharringtonine-perspectives on an active new natural product. J Clin Oncol 1986; 4: 1563-1568.
39. Zeng SQ, Hu CZ, Lu YS, Tian XH. Ocular toxicity study of intravitreal harringtonine. Chinese J Ocular Fundus Dis 1990; 6: 138-141.
40. Myers CE, Corden B, Gianni L. Anti-tumor antibiotics. I. Anthracyclines. In: Chabner BA, Pinedi HM, eds. The Cancer Pharmacology Annual 2. Amsterdam: Elsevier, 1984, pp. 66-79.
41. Kirmani M, Santana M, Sorgente N, Bekhor C, Patterson R, Tran T, et al. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy. Retina 1983; 3: 269-272.
42. Wiedemann P, Leimung C, Hilgers RD, Heimann K. Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. Graefe's Arch Clin Exp Ophthalmol 1991; 229: 150-152.
43. Sanatana M, Wiedemann P, Kirmani M. Daunomycin in the treatment of periodical proliferative vitreoretinopathy: Retinal toxicity of intravitreal daunomycin in the rabbit. Graefes Arch Clin Exp Ophthalmol 1984; 221: 210-213.
44. Wiedemann P, Sorgente N, Bekhor C, Patterson R, Tran T, Ryan SJ. Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo. Invest Ophthalmol Vis Sci 1985; 26: 719-725.
45. Weller M, Heimann K, Wiedemann P. Cytotoxic effects of daunomycin on retinal pigment epithelium in vitro. Graefe's Arch Clin Exp Ophthalmol 1987; 225: 235-238.
46. Blumenkranz MS, Ophir A, Claflin AJ, Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol 1982; 94: 458-467.
47. Assil KK, Weinreb RN. Multivesicular liposomes: Sustained release of the antimetabolite cytarabine in the eye. Arch Ophthalmol 1987; 105: 400-403.
48. Barza M, Stuart M, Szoka F. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposones. Invest Ophthalmol Vis Sci 1987; 28: 893-900.
49. Lewis H, Schwartz S, Lee D. The use of bioerodible polymer and 5-fluorouracil in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1991; 32(suppl): 1047.
50. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial. Ophthalmology 2001; 108: 1179-1183.
51. Hatchell DL, McAdoo T, Shetá S, King RT, Bartolome JV Quantification of cellular proliferation in experimental proliferative vitreoretinopathy. Arch Ophthalmol 1988; 106: 641-672.